

Neeraj Gupta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5029199/publications.pdf>

Version: 2024-02-01

67
papers

3,069
citations

236925

25
h-index

161849

54
g-index

69
all docs

69
docs citations

69
times ranked

3261
citing authors

#	ARTICLE	IF	CITATIONS
1	Asiaâ€inclusive Clinical Research and Development Enabled by Translational Science and Quantitative Clinical Pharmacology: Toward a Culture That Challenges the Status Quo. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 298-309.	4.7	7
2	A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. <i>Targeted Oncology</i> , 2022, 17, 15-24.	3.6	7
3	Population pharmacokinetic and exposureâ€response analyses from ALTAâ€1L: Modelâ€based analyses supporting the brigatinib dose in <i>ALK</i>-positive NSCLC. <i>Clinical and Translational Science</i> , 2022, 15, 1143-1154.	3.1	7
4	Assessment of Effects of Investigational TAKâ€931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2022, , .	1.6	2
5	Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinaseâ€positive nonâ€small cell lung cancer. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3922-3923.	2.4	1
6	Population pharmacokinetics of mobocertinib in healthy volunteers and patients with nonâ€small cell lung cancer. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 731-744.	2.5	6
7	Mobocertinib Dose Rationale in Patients with Metastatic NSCLC with <i>EGFR</i> Exon 20 Insertions: Exposureâ€Response Analyses of a Pivotal Phase I/II Study. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 327-334.	4.7	7
8	Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINEâ€MM1 study in multiple myeloma patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2022, 11, 1085-1099.	2.5	4
9	Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer. <i>Clinical Pharmacokinetics</i> , 2021, 60, 235-247.	3.5	15
10	Effect of severe renal impairment on the pharmacokinetics of brigatinib. <i>Investigational New Drugs</i> , 2021, 39, 1306-1314.	2.6	7
11	Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAKâ€788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1044-1053.	1.6	13
12	Singleâ€Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAKâ€788) in Healthy Volunteers: Lowâ€Fat Meal Effect and Relative Bioavailability of 2 Capsule Products. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1028-1043.	1.6	11
13	Population Pharmacokinetics of TAKâ€931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2021, , .	2.0	4
14	Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 214-223.	1.6	19
15	Transforming Translation Through Quantitative Pharmacology for Highâ€Impact Decision Making in Drug Discovery and Development. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1285-1289.	4.7	10
16	Brigatinib Dose Rationale in Anaplastic Lymphoma Kinaseâ€Positive Nonâ€Small Cell Lung Cancer: Exposureâ€Response Analyses of Pivotal ALTA Study. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 718-730.	2.5	15
17	Brigatinib Versus Crizotinib in Advanced ALK Inhibitorâ€Naive ALK-Positive Nonâ€Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3592-3603.	1.6	224
18	Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1190-1199.	1.1	23

#	ARTICLE	IF	CITATIONS
19	Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor. <i>Clinical Pharmacokinetics</i> , 2019, 58, 431-449.	3.5	45
20	The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 734-741.	1.6	19
21	All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>European Journal of Cancer</i> , 2019, 106, 89-98.	2.8	25
22	Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2019, 184, 536-546.	2.5	16
23	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 393, 253-264.	13.7	187
24	Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 376-387.	4.7	7
25	Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development. <i>Clinical and Translational Science</i> , 2018, 11, 123-146.	3.1	36
26	Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 378-383.	4.7	23
27	A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2018, 36, 407-415.	2.6	15
28	Model-Based Meta-Analysis for Multiple Myeloma: A Quantitative Drug-Independent Framework for Efficient Decisions in Oncology Drug Development. <i>Clinical and Translational Science</i> , 2018, 11, 218-225.	3.1	9
29	A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 114-121.	2.0	5
30	Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 180-192.	2.0	33
31	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2027-2039.	27.0	691
32	A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma. <i>Haematologica</i> , 2018, 103, 1518-1526.	3.5	18
33	Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244.	2.5	30
34	Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 803-814.	2.3	6
35	Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range. <i>Journal of Clinical Pharmacology</i> , 2017, 57, 1183-1193.	2.0	15
36	Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. <i>British Journal of Haematology</i> , 2017, 178, 571-582.	2.5	45

#	ARTICLE	IF	CITATIONS
37	A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. <i>Blood</i> , 2017, 130, 597-605.	1.4	108
38	Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1355-1368.	3.5	40
39	Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. <i>Targeted Oncology</i> , 2017, 12, 643-654.	3.6	19
40	The Oral Proteasome Inhibitor Ixazomib in Combination with Melphalan-Prednisone (MP) for Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 1/2 Dose-Escalation Study (NCT01335685). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S337-S338.	0.4	1
41	New developments in the management of relapsed/refractory multiple myeloma – the role of ixazomib. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 107-121.	1.7	19
42	Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study. <i>Journal of Hematology and Oncology</i> , 2017, 10, 137.	17.0	56
43	Exposure"safety" efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study. <i>Investigational New Drugs</i> , 2016, 34, 338-346.	2.6	19
44	The Effect of a High"Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1288-1295.	2.0	34
45	Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 728-738.	2.4	38
46	A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end"stage renal disease requiring haemodialysis. <i>British Journal of Haematology</i> , 2016, 174, 748-759.	2.5	48
47	Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2016, 128, 3327-3327.	1.4	8
48	Switching from body surface area"based to fixed dosing for the investigational proteasome inhibitor ixazomib: a population pharmacokinetic analysis. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 789-800.	2.4	50
49	Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies. <i>Investigational New Drugs</i> , 2015, 33, 652-663.	2.6	35
50	The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. <i>Future Oncology</i> , 2015, 11, 1153-1168.	2.4	25
51	Pharmacokinetics and safety of ixazomib plus lenalidomide"dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. <i>Journal of Hematology and Oncology</i> , 2015, 8, 103.	17.0	37
52	Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 507-516.	2.3	21
53	Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma. <i>Blood Cancer Journal</i> , 2014, 4, e251-e251.	6.2	43
54	Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. <i>Blood</i> , 2014, 124, 1038-1046.	1.4	192

#	ARTICLE	IF	CITATIONS
55	Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1503-1512.	10.7	233
56	Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. <i>Blood</i> , 2014, 124, 1047-1055.	1.4	185
57	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. <i>Blood</i> , 2013, 122, 535-535.	1.4	18
58	A drug-drug interaction study between the strong CYP3A4 inhibitor ketoconazole (keto) and ixazomib citrate (MLN9708), an investigational, orally active proteasome inhibitor, in patients with advanced solid tumors or lymphoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2555-2555.	1.6	2
59	A Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously Untreated Multiple Myeloma (MM). <i>Blood</i> , 2012, 120, 332-332.	1.4	12
60	Results of a Phase 1 Dose-Escalation Study of Once-Weekly MLN9708, an Investigational Proteasome Inhibitor, in Patients with Relapsed/Refractory Lymphoma. <i>Blood</i> , 2012, 120, 3646-3646.	1.4	3
61	MLN9708, a Novel, Investigational Oral Proteasome Inhibitor, in Patients with Relapsed or Refractory Light-Chain Amyloidosis (AL): Results of a Phase 1 Study. <i>Blood</i> , 2012, 120, 731-731.	1.4	12
62	Tumor drug distribution and target engagement of MLN9708, an investigational proteasome inhibitor, in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, 3077-3077.	1.6	13
63	Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. <i>European Journal of Cancer</i> , 2011, 47, 2706-2714.	2.8	33
64	Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1418-1425.	1.1	59
65	Flat-Dosing Versus BSA-Based Dosing for MLN9708, An Investigational Proteasome Inhibitor: Population Pharmacokinetic (PK) Analysis of Pooled Data From 4 Phase-1 Studies. <i>Blood</i> , 2011, 118, 1433-1433.	1.4	6
66	Clinical Pharmacokinetics of Intravenous and Oral MLN9708, An Investigational Proteasome Inhibitor: An Analysis of Data From Four Phase 1 Monotherapy Studies. <i>Blood</i> , 2010, 116, 1813-1813.	1.4	5
67	Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2009, 27, 4718-4726.	1.6	87